Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2022 08:30 ET | Source: Albireo Pharma, Inc.

Albireo Appoints New Members to Board of Directors

– Habib Dable, Former President and CEO of Acceleron Pharma, and Susan Alesina, Vice President, National Business Development and Alliances at Boston Children’s Hospital, bring significant global drug...
August 03, 2022 08:30 ET | Source: Albireo Pharma, Inc.

Albireo to Participate in 2022 Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...
August 01, 2022 08:30 ET | Source: Albireo Pharma, Inc.

Albireo to Report Q2 2022 Financial Results on August 15, 2022

BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a...
July 26, 2022 16:30 ET | Source: Albireo Pharma, Inc.

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the grant of inducement restricted...
July 06, 2022 08:30 ET | Source: Albireo Pharma, Inc.

The Lancet Gastroenterology & Hepatology Publishes Data from Albireo’s Landmark PEDFIC 1 Study of Bylvay® (odevixibat) Treatment in PFIC

First successful global gold standard pediatric Phase 3 trial ever conducted in cholestatic liver disease PEDFIC 1 & 2 studies were foundational for the approval of Bylvay in the U.S. and Europe...
June 30, 2022 08:00 ET | Source: Albireo Pharma, Inc.

Albireo to Present at the William Blair Biotech Focus Conference 2022

BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation at the William Blair...
June 24, 2022 08:30 ET | Source: Albireo Pharma, Inc.

Albireo Presents New Bylvay® (odevixibat) Data at Annual ESPGHAN Congress

Four presentations highlight newest data from landmark Phase 3 PEDFIC 1 and PEDFIC 2 trials, largest studies completed in PFICNew analysis show potential for greater response and higher proportion of...
June 23, 2022 08:30 ET | Source: Albireo Pharma, Inc.

Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases

New analyses of PEDFIC Phase 3 trials show that patients whose pruritus improves on Bylvay® (odevixibat) also experience improvements in sleep, quality of life, serum bile acids and hepatic...
June 08, 2022 08:30 ET | Source: Albireo Pharma, Inc.

Albireo to Present New Data at the EASL International Liver Congress™ 2022

– Five abstracts accepted, long-term data confirmed durable efficacy with Bylvay™ (odevixibat), with demonstrated improvement in quality of life, growth, and sleep measurements, and hepatic biomarkers...
June 07, 2022 08:30 ET | Source: Albireo Pharma, Inc.

Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN

– Four abstracts accepted of Phase 3 data from PEDFIC 1 and PEDFIC 2 trials of Bylvay™ (odevixibat) – Three oral presentations discuss long-term safety, tolerability and improved quality of life,...